6. Ludwig Kappos, Giancarlo Comi, Krzysztof W. Selmaj, et al. Evaluating No Evidence of Disease Activity in Patients With Relapsing Multiple Sclerosis: Post Hoc Analysis of the Phase 3 RADIANCE and Open-Label Extension S...
参考来源: Roche’s fenebrutinib demonstrated near-complete suppression of disease activity and disability progression for up to 48 weeks in patients with relapsing multiple sclerosis.https://www.biospace.com/press-releases/roch...
Background The CLARITY study in patients with RMS allows assessment of high disease activity (HDA) definitions for identifying patients with higher rate of relapse or disability progression. Objective Evaluate clinical/MRI criteria to identify HDA among placebo recipients in CLARITY. Methods Placebo ...
Indication: Rebif®is a prescription medicine used to treat relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. It is not known if Rebif is safe and effective in children. ...
TYSABRI is a prescription medicine used to treat relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. TYSABRI increases the risk of progressive multifocal leukoencephalopathy (PML). When starting and conti...
Considering TYSABRI The TYSABRI Spirit The TYSABRI Experience Biogen Support Services What is TYSABRI? TYSABRI is a prescription medicine used to treat relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease....
COPAXONE is a prescription medicine that is used to treat relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. It is not known if COPAXONE is safe and effective in children under 18 ye...
Ocrelizumab and hyaluronidase is now the first and only twice-yearly subcutaneous injection approved for relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS).
Multiple sclerosis (MS) is a chronic, inflammatory condition of the central nervous system and is the most common non-traumatic, disabling neurological disease in young adults. It is estimated that approximately 2.8 million people have MS worldwide. While symptoms can vary, the most common symptoms...
RMSRelapsing Multiple Sclerosis(disease) RMSRoot Management Server RMSRestaurant Management System(Point of Sale) RMSRevenue Market Share RMSReference Member State RMSReliability Management System(Western Systems Coordinating Council initiative for assuring reliable electric power) ...